Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PAC 113

Drug Profile

PAC 113

Alternative Names: P 113L; PAC-113; PAC-113 Mouth Rinse

Latest Information Update: 22 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Demegen
  • Developer Demegen; General Biologicals Corporation; Pacgen Life Science Corporation
  • Class Antibacterials; Antifungals; Peptide antibiotics; Peptides
  • Mechanism of Action Cell membrane permeability enhancers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Candidiasis
  • Discontinued Gingivitis; Mucositis

Most Recent Events

  • 22 Jul 2016 Phase-II clinical trials in Candidiasis in Taiwan (PO) before July 2016
  • 24 Jan 2014 Pacgen Life Science enter into a sublicensing agreement with General Biological Corporation for PAC 113 for any oral condition (excluding transitional skin-mucous membrane areas) and also for vaginal, dermatological and ophthalmic conditions
  • 30 Apr 2012 Pacgen Biopharmaceuticals is now called Pacgen Life Science Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top